Rheumatoid arthritis: Biological therapy other than anti-TNF
- PMID: 25840282
- DOI: 10.1016/j.intimp.2015.03.019
Rheumatoid arthritis: Biological therapy other than anti-TNF
Abstract
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases and is characterized by synovitis that causes joint damage. The introduction of biologic agents has made it possible to induce remission in many patients and inhibit joint damage. Activated T cells in RA patients proliferate and stimulate the production of pro-inflammatory cytokines including tumor necrosis factor (TNF) and interleukin 6 that play important roles in RA pathogenesis. The most widely used biologic agents indicated for RA inhibit the activity of TNF. However, newly developed biologic drugs targeting different pathways are now currently part of the therapeutic options to induce remission in patients with RA. The present review focuses on biologic agents directed at molecular targets different from TNF and addresses the possible advantages of these drugs.
Keywords: Abatacept; Anti-IL6; Rheumatoid arthritis; Rituximab; Tocilizumab.
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
-
[The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].Pol Merkur Lekarski. 2011 Apr;30(178):289-94. Pol Merkur Lekarski. 2011. PMID: 21595177 Review. Polish.
-
[New therapies for rheumatoid arthritis].Med Clin (Barc). 2014 Nov 18;143(10):461-6. doi: 10.1016/j.medcli.2013.11.011. Epub 2014 Jan 22. Med Clin (Barc). 2014. PMID: 24461738 Review. Spanish.
-
Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.PLoS One. 2019 Jul 24;14(7):e0220142. doi: 10.1371/journal.pone.0220142. eCollection 2019. PLoS One. 2019. PMID: 31339961 Free PMC article.
-
Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.Int J Rheum Dis. 2016 Nov;19(11):1093-1102. doi: 10.1111/1756-185X.12845. Epub 2016 Mar 27. Int J Rheum Dis. 2016. PMID: 27018857
-
Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.Arthritis Res Ther. 2015 Nov 11;17:319. doi: 10.1186/s13075-015-0835-7. Arthritis Res Ther. 2015. PMID: 26555431 Free PMC article.
Cited by
-
The Human Replicative Helicase, the CMG Complex, as a Target for Anti-cancer Therapy.Front Mol Biosci. 2018 Mar 29;5:26. doi: 10.3389/fmolb.2018.00026. eCollection 2018. Front Mol Biosci. 2018. PMID: 29651420 Free PMC article. Review.
-
Role of interleukin-6-mediated inflammation in the pathogenesis of inflammatory bowel disease: focus on the available therapeutic approaches and gut microbiome.J Cell Commun Signal. 2023 Mar;17(1):55-74. doi: 10.1007/s12079-022-00695-x. Epub 2022 Sep 16. J Cell Commun Signal. 2023. PMID: 36112307 Free PMC article. Review.
-
Curculigoside exerts significant anti‑arthritic effects in vivo and in vitro via regulation of the JAK/STAT/NF‑κB signaling pathway.Mol Med Rep. 2019 Mar;19(3):2057-2064. doi: 10.3892/mmr.2019.9854. Epub 2019 Jan 14. Mol Med Rep. 2019. PMID: 30664158 Free PMC article.
-
Biofunctional Nanofibrous Substrate for Local TNF-Capturing as a Strategy to Control Inflammation in Arthritic Joints.Nanomaterials (Basel). 2019 Apr 8;9(4):567. doi: 10.3390/nano9040567. Nanomaterials (Basel). 2019. PMID: 30965588 Free PMC article.
-
Cytokine Targeting by miRNAs in Autoimmune Diseases.Front Immunol. 2019 Jan 29;10:15. doi: 10.3389/fimmu.2019.00015. eCollection 2019. Front Immunol. 2019. PMID: 30761124 Free PMC article. Review.
